Please do not adjust margins
ChemComm
Page 4 of 4
COMMUNICATION
Journal Name
N. Kwon, Chem. Commun. 2019, 55, 12316.
the therapeutic effect of the DPAC-S@CB[7]@CPPO. In addition,
because mitochondria are more susceptible to 1O2 damage than
other organelles, mitochondrial-targeted DPAC-S@CB[7]@CPPO
can maximize PDT outcome. 21
DOI: 10.1039/D0CC01868F
Fischer, C. Reichardt, M. Kogler, B. Dietzek, M. Feuring-Buske, C.
Buske, S. Rau and T. Weil, J. Am. Chem. Soc. 2017, 139, 2512; b) N.
Cheng, Y. Chen, J. Yu, J. J. Li and Y. Liu, Bioconjugate Chem. 2018, 29,
1829.
[3] Á. Juarranz, P. Jaén, F. Sanz-Rodríguez, J. Cuevas and S.
González, Clin. Transl. Oncol. 2008, 10, 148.
[4] a) M. Ethirajan, Y. Chen, P. Joshi and R. K. Pandey, Chem. Soc.
Rev. 2011, 40, 340; b) G. Gollavelli and Y. C. Ling, Biomaterials 2014,
35, 4499.
[5] H. Chen, J. Zhang, K. Chang, X. Men, X. Fang, L. Zhou, D. Li, D.
Gao, S. Yin, X. Zhang, Z. Yuan and C. Wu, Biomaterials 2017, 144, 42.
[6] J. M. Baumes, J. J. Gassensmith, J. Giblin, J.-J. Lee, A. G. White,
W. J. Culligan, W. M. Leevy, M. Kuno and B. D. Smith, Nat. Chem.
2010, 2, 1025.
[7] a) D. Lee, S. Khaja, J. C. Velasquez-Castano, M. Dasari, C. Sun, J.
Petros, W. R. Taylor and N. Murthy, Nat. Mater. 2007, 6, 765; b) A. J.
Shuhendler, K. Pu, L. Cui, J. P. Uetrecht and J. Rao, Nat. Biotechnol.
2014, 32, 373.
[8] a) A. Jezierska-Drutel, S. A. Rosenzweig and C. A. Neumann, Adv.
Cancer. Res. 2013, 119, 107; b) H. Yuan, H. Chong, B. Wang, C. Zhu,
L. Liu, Q. Yang, F. Lv and S. Wang, J. Am. Chem. Soc. 2012, 134,
13184.
The viability of 293T and KYSE-150 cells treated with DPAC-
S@CB[7]@CPPO was assessed by CCK8.22 Two types of cell lines
(KYSE-150 and 293T) were use to evaluate the cytotoxic effects of
DPAC-S@CB[7]@CPPO at a cellular level (Figure 4b). Under dark
conditions, the DPAC-S@CB[7]@CPPO was incubated with KYSE-150
and 293T for 24 hours, respectively. The incubation of DPAC-
S@CB[7]@CPPO with 293T cells revealed that the cell viability
remained around 100% throughout the incubation period,
indicating that DPAC-S@CB[7]@CPPO was nontoxic to the normal
cell. However, the cell toxicity to KYSE-150 increased with increase
of the concentration of the DPAC-S@CB[7]@CPPO. It speculates
that the different toxicity of assemblies to two types of cells is
related to the concentration of H2O2 produced in the physiological
process of cells. Tumor cells can rapidly produce a large amount of
H2O2, which enables DPAC-S@CB[7]@CPPO to effectively produce
chemiluminescence and PDT effects.23 Furthermore, by adding 1
mM H2O2 to simulate the microenvironment of tumor tissues, the
cytotoxicity of the assembly was further enhanced by H2O2, which
means that therapeutic effect of the DPAC-S@CB[7]@CPPO is
positively correlated with the concentration of H2O2 in the tumor.
These phenomena indicate that the assembly has specific toxicity to
cancer cells, which makes the assembly have a greater application
prospect as a treatment of cancer.
In conclusion, we have successfully constructed mitochondrial-
targeted chemiluminescent supramolecular assembly for in situ PDT
through photosensitizer DPAC-S, macrocyclic molecule CB[7] and
CPPO. The good water solubility and biocompatibility of the
assembly enable it to enter cells. In addition, positive charges on
the surface of the assembly give it the ability to target
mitochondria. Mitochondrial H2O2 can rapidly activate CPPO
molecules to generate energy after entering cancer cells and its
energy can be effectively absorbed by nearby DPAC-S to lead
chemiluminescence and 1O2 generation in suit to kill cancer cells.
The results show that the PDT effect produced by
chemiluminescent supramolecular assembly is specific to cancer
cells. This work effectively solves the dependence of traditional PDT
on external light source, and provides an effective reference for the
treatment of deep tissue tumors.
[9] D. Mao, W. Wu, S. Ji, C. Chen, F. Hu, D. Kong, D. Ding and B. Liu,
Chem 2017, 3, 991.
[10]
553.
[11]
H.B. Cheng, Y.M. Zhang, Y. Liu and J. Yoon, Chem, 2019, 5,
W. Chen, C. L. Chen, Z. Zhang, Y. A. Chen, W. C. Chao, J. Su,
H. Tian, P. T. Chou, J. Am. Chem. Soc. 2017, 139, 1636-1644.
[12]
a) J. J. Li, H. Y. Zhang, Y. Zhang, W. L. Zhou and Y. Liu, Adv.
Opt. Mater. 2019, 1900589; b) Y. M. Zhang, J. H. Liu, Q. Yu, X. Wen
and Y. Liu, Angew. Chem., Int. Ed. 2019, 58, 10553; c) Y. M. Zhang, Y.
H. Liu and Y. Liu, Adv. Mater. 2019, 37,843.
[13]
J. J. Li, Y. Chen, J. Yu, N. Cheng and Y. Liu, Adv. Mater. 2017,
29, 1701905.
[14] a) X. Guan, Y. Chen, X. Wu, P. Li and Y. Liu, Chem. Commun.
2019, 55, 953; b) J. H. Liu, X. Wu, Y. M. Zhang and Y. Liu, Asian. J.
Org. Chem. 2018, 7, 2444.
[15]
Peng, J. Am. Chem. Soc. 2018, 140, 15820.
[16] a) H. Wu, Y. Chen, X. Dai, P. Li, J. F. Stoddart and Y. Liu, J. Am.
M. Li, S. Long, Y. Kang, L. Guo, J. Wang, J. Fan, J. Du and X.
Chem. Soc. 2019, 141, 6583; b) Z. Y. Zhang, Y. Chen and Y. Liu,
Angew. Chem., Int. Ed. 2019, 58, 6028; c) X. M. Chen, Y. Chen, Q. Yu,
B. H. Gu and Y. Liu, Angew. Chem., Int. Ed. 2018, 57, 12519.
[17] a) J. Wang, X. Yao, Y. Liu, H. Zhou, W. Chen, G. Sun, J. Su, X.
Ma and H. Tian, Adv. Opt. Mater. 2018, 6, 1800074; b) Z. Zhang, C.
L. Chen, Y. A. Chen, Y. C. Wei, J. Su, H. Tian and P. T. Chou, Angew.
Chem., Int. Ed. 2018, 57, 9880.
We thank NNSFC (Nos. 21672113, 21772099, 21861132001
and 21971127) for financial support.
[18]H.P. Tham, H. Chen, Y. H. Tan, Chem. Commun. 2016, 52: 8854.
[19]
Y. D. Lee, C. K. Lim, A. Singh, J. Koh, J. Kim, I. C. Kwon and S.
Kim, ACS .Nano. 2012, 6, 6759.
[20]
K. Xu, M. Qiang, W. Gao, R. Su, N. Li, Y. Gao, Y. Xie, F. Kong
Conflicts of interest
There are no conflicts to declare.
and B. Tang, Chem. Sci. 2013, 4, 1079.
[21]
W. Lv, Z. Zhang, K. Y. Zhang, H. Yang, S. Liu, A. Xu, S. Guo, Q.
Zhao and W. Huang, Angew. Chem., Int. Ed. 2016, 55, 9947.
[22] Q. Yu, Y.-M. Zhang, Y.-H. Liu, X. Xu and Y. Liu, Sci. Adv. 2018,
4, eaat2297.
[23] T. P. Szatrowski, C. F. Nathan, Cancer. Res. 1991, 51, 794.
Notes and references
[1] a) C. Ji, Q. Gao, X. Dong, W. Yin, Z. Gu, Z. Gan, Y. Zhao and M.
Yin, Angew. Chem., Int. Ed. 2018, 57, 11384; b) C. Qian, J. Yu, Y.
Chen, Q. Hu, X. Xiao, W. Sun, C. Wang, P. Feng, Q. D. Shen and Z. Gu,
Adv. Mater. 2016, 28, 3313; c) M. Yang, T. Yang and C. Mao, Angew.
Chem., Int. Ed. 2019, 58, 14066; (d) X. Li, S. Lee, J. Yoon ,Chem. Soc.
Rev. 2018, 47, 1174; (e) X.. Li, Yu. S, Lee, J. Yoon, J. Am. Chem. Soc.
2018, 141, 1366; (f) X. Li, S .Yu, D. Lee, ACS Nano, 2018, 12, 681; (g)
X. Li, H. Bai, Y. Yang, Adv. Mater. 2019, 31, 1805092; (h) Z. H. Yu, X.
Li, F. Xu, Angew. Chem., Int. Ed, 2020, 59, 3658; (i) H. B. Cheng, X. Li,
4 | J. Name., 2012, 00, 1-3
This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins